As part of the agreement Polyphor will use its MacroFinder drug discovery technology to identify and optimize macrocyclic drug candidate addressing therapeutic targets selected by Boehringer.
Boehringer will offer Polyphor an advance payment, research fund and payments of milestone under the agreement.
In addition, Polyphor is entitled for unrevealed royalties on the sales of products approved.
Polyphor CEO Jean-Pierre Obrecht said,"I take pride in this agreement, which is testament to a trustful business relationship of more than 10 years. Boehringer Ingelheim has an excellent reputation in the industry and the conclusion of this agreement therefore constitutes both a scientific and commercial validation of the MacroFinder platform.”
Polyphor CSO Daniel Obrecht said,"I very much look forward to this collaboration and I am confident that combining Boehringer Ingelheim’s excellent R&D capabilities with Polyphor’s MacroFinder drug discovery platform will allow the two parties to develop potent and selective MacroFinder compounds able to effectively modulate challenging therapeutic targets and hopefully provide innovative treatments with significant therapeutic benefit to the patients."
MacroFinder provides synthetic,macrocyclic molecules able to modulate biological targets which includes intra and extracellular protein-protein interactions.